All News
Do you consider ttmt successful? Question Christeen et al. asked to 100+ PsA pts. 1/3 pts said no, they had > TJC, > SJC, > Pso & > dactylitis.
Failure also w/: pain 24%, pso 15%, fatigue 12% and < ability to be active 9%.
https://t.co/dQseCNSDBS Abstr #0393 #ACR22 @Rheumnow https://t.co/kGlmscsKL7
Aurelie Najm AurelieRheumo ( View Tweet)
MACE and VTE from 9 (6 RA, 2 PsA, 1 AS) RCTs w/ UPA.
6000+ pts received UPA 40-50% w/ > or = 2 BL CV risk factors.
41 MACE UPA 15mg RA-PsA group & 2 fatal VTE UPA 15mg RA group.
Overlapping confidence intervals w/ADA & MTX.
https://t.co/7xtZlDIkVu
Abs#0510 #ACR22 @Rheumnow https://t.co/reywXk5Z0Z
Aurelie Najm AurelieRheumo ( View Tweet)
RECITAL trial comparing ritux vs cyclo for CTD-ILD. This is a sub-group analysis of larger trial. 1/n
@RheumNow #ACR22 #Plenary
Julian Segan JulianSegan ( View Tweet)
GPA is a rare cause of both submandibular gland enlargement and dacryoadenitis. Can look like IgG4RD and Sjogrens.
@RheumNow #ACR22 #Pearls https://t.co/Gw6OF4H2w2
Julian Segan JulianSegan ( View Tweet)
Are my patients represented in PsA trials? @RheumNow #ACR22
Abstract #0090; Ignite Talk
☝️Of 25 RCT from 2002-2022, only 13 included patients of non-White race
☝️Hispanic/Latinx ethnicity was reported in 0 studies
☝️Black individuals represented < 1% patients included
Catherine Sims, MD DrCassySims ( View Tweet)
Dr. John Stone pronounces GiACTA “GEE-ACTA”. I have been pronouncing it “GIA-ACTA” and will now correct myself #vasculitis #ACR22
Catherine Sims, MD DrCassySims ( View Tweet)
#ACR22 Year in Review. Dr Langford summarised significant progress attained in 2022 in combating #COVID and protect our immunosuppressed patients @RheumNow https://t.co/lZSDRj3bkm
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Key points in managing MDA5+ DM
1. Monitor lungs - HRCT/PFTs
2. Test muscle endurance (ref: IMACS site) not just strength
3. Close observation
4. MTX/MMF initial treatments
5. Repeat muscle biopsy if diagnosis unclear
Meet the Expert Lundberg I, IMM session @RheumNow #ACR22 https://t.co/ZVFsYgDBx2
Dr. Antoni Chan synovialjoints ( View Tweet)
Key points in managing MDA5+ DM
1. Consider Tofacitinib 5-10mg bd
2. Low to mid dose Prednisolone 20-30mg tapering
3. Other Rx: Tacrolimus, IVIG
4. Poor prognostic factors: lymphopenia, raised ferritin, old age, rapid ILD progression
Wang GC, IIM session @RheumNow #ACR22 https://t.co/UF2PjAg0Mw
Dr. Antoni Chan synovialjoints ( View Tweet)
Therapies for AS and nr-AxSpA are coming together. Both AS and nr-AxSpA present with similar burden of disease. TNFi, IL-17i and JAKi now approved for use in nr-AxSpA.
Jose U Scher, SpA Review @RheumNow #ACR22 https://t.co/vcHcd7OyAU
Dr. Antoni Chan synovialjoints ( View Tweet)
Mimics of Sjogren’s Syndrome @RheumNow #ACR22 https://t.co/nEAXKb6qF0
Dr. Antoni Chan synovialjoints ( View Tweet)
“The Stone Age did not end because of a shortage of stones. We need new solutions to our problems” Abraham Verghese. Amazing insight into our challenges in clinic today at the #ACR22 opening session @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
GCA Fast Track clinics are nice - but usually need specialized ultrasound.
What if you don't have it? (also, COVID?)
@PennRheum implemented *without* ultrasound
Excellent outcomes
The early referral triage makes all the difference. Knowledge is power ABST0463 #ACR22 @RheumNow https://t.co/rjkVERW559
David Liew drdavidliew ( View Tweet)
More details at https://t.co/4U8v7oeUYW
Enormously powerful in these times of rheumatology workforce shortage. I would love to see this in Australia and elsewhere - so much to learn. Congratulations to all involved, and thanks @ACRheum and @UCSF for supporting #ACR22
David Liew drdavidliew ( View Tweet)
Just published! QR code attached! #ACR22 @RheumNow https://t.co/lMD0mFoT4M
Patricia Harkins DrTrishHarkins ( View Tweet)
“Rheumatic diseases - diseases of accelerated aging”
With age:
⚖️ fat ⬆️
💪🏻 muscle ⬇️
👉 results in ⬇️fn ⬇️gait speed ⬇️grip
🌟what can we do?
⚡️start with basic diet and exercise advice
✅caloric restriction (⬇️350cal/day)
✅ resistance training
#GeriRheum #ACR22 https://t.co/6KRrwCWBEZ
Patricia Harkins DrTrishHarkins ( View Tweet)
Botson et al. 52 week results MIRROR trial. MTX added to pegloticase. 71% vs 39% SU <6mg/dl. Infusion reaction 13% vs 32% if ab+ 0% vs 30% ab- @RheumNow #ACR22 Abstr#0001 #ACRbest https://t.co/1c3Va9NxNX https://t.co/dPGDyWue4G
Richard Conway RichardPAConway ( View Tweet)
England et al. Influence of FVC on choice of b/tsDMARD in RA-ILD. FVC predicts hospitalisation and mortality. However, it did not appear to influence choice of b/tsDMARD. Overall 67% of RA-ILD patients initiated TNFi, weird! @rheumnow #ACR22 Abstr#245 https://t.co/swuNHv96WD https://t.co/vy5FUPnNjo
Richard Conway RichardPAConway ( View Tweet)
Interesting observation: Late-onset PsA assoc'd w/ male sex, greater structural damage, higher frequency of arthritis, and greater loss of functionality (BASFI). Interestingly, shorter time of symptom duration to dx. Abs 0377 #ACR22 @RheumNow https://t.co/m15c37FltD https://t.co/3LRy4Ltde6
Dr. Rachel Tate uptoTate ( View Tweet)
#ClinicalPearl #Methotrexate is recommended for Rx in all EXCEPT…#ACR22 @RheumNow
Janet Pope Janetbirdope ( View Tweet)